Henagliflozin Explained
| Drug Name: | Henagliflozin |
| Tradename: | Rui Qin; 瑞沁 |
| Legal Status: | Rx in China |
| Synonyms: | SHR3824; SHR-3824 |
| Cas Number: | 1623804-44-3 |
| Pubchem: | 56832738 |
| Unii: | 21P2M98388 |
| Drugbank: | DB11939 |
| Iupac Name: | (1R,2S,3S,4R,5R)-5-[4-Chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol |
| C: | 22 |
| H: | 24 |
| Cl: | 1 |
| F: | 1 |
| O: | 7 |
Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2] [3]
Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]
Notes and References
- Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J . Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial . Diabetes, Obesity & Metabolism . 23 . 8 . 1754–1764 . August 2021 . 33769656 . 10.1111/dom.14389 .
- Web site: Wang G . 17 February 2022. Monthly Report: New Drug Approvals in China, January 2022 . BaiPharm . Henagliflozin Proline Tablets .
- Web site: Henagliflozin - Jiangsu HengRui Medicine . AdisInsight . Springer Nature Switzerland AG .
- He X, Liu G, Chen X, Wang Y, Liu R, Wang C, Huang Y, Shen J, Jia Y . Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects . Clinical Therapeutics . 45 . 7 . 655–661 . July 2023 . 37451912 . 10.1016/j.clinthera.2023.06.002 .
